...company liquidated and filed a certificate of dissolution last August (see BioCentury, Sept. 2, 2013). Maxygen...

...society are immeasurable. The many companies he formed (Alza, Affymax, Alexza, Affymetrix, Dynapol, DNAX, Symyx, Maxygen...

...Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve...
...the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen...
...certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen...

...three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. Maxygen's...
...company said it has no plans to independently continue development of MAXY-G34 for either indication. Maxygen Inc....

...small molecule kinase-targeted drug discovery for cancer. Perseid was formed under a 2009 JV with Maxygen Inc....
...Genentech Inc. , South San Francisco, Calif. High Energy Accelerator Research Organization , Tsukuba, Japan Maxygen Inc....
...OSI Pharmaceuticals Inc. and the remaining stake in Perseid Therapeutics LLC, a JV with Maxygen Inc....

...from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's...
...of recombinant Factor VIIa product (formerly MAXY-VII) and after undisclosed patent related conditions were met. Maxygen...
...is not eligible for any further payments under the deal (see BioCentury, July 7, 2008). Maxygen Inc....

...and €15.2 million ($19.5 million) in a private placement of 6.6 million shares at €2.30. Maxygen Inc....
...milestone payment from Bayer AG (Xetra:BAYN) under a 2008 deal in which the pharma acquired Maxygen's...

...million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc....

...and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen...
...overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen...
...that cover mutated G-CSF molecules, which Maxygen said may cover MAXY-G34 (see BioCentury, Oct. 17). Maxygen Inc....